|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #redirect [[Lovastatin#Adverse Reactions]] |
| {{Lovastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| The following serious adverse reactions are discussed in greater detail in other sections of the label:
| |
| | |
| *Rhabdomyolysis and myopathy [see Warnings and Precautions (5.1)]
| |
| *Liver enzyme abnormalities [see Warnings and Precautions (5.2)]
| |
| | |
| ===Clinical Trial Adverse Reactions===
| |
| | |
| Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
| |
| | |
| In controlled clinical trials with Altoprev®, 467 patients who received Altoprev®, <3% of patients were discontinued due to adverse experiences attributable to Altoprev®. This was similar to the discontinuation rate in the placebo and lovastatin immediate-release treatment groups.
| |
| | |
| Pooled results from clinical trials with Altoprev® show that the most frequently reported adverse reactions in the Altoprev® group were infection, headache and accidental injury. Similar incidences of these adverse reactions were seen in the lovastatin and placebo groups. In controlled clinical trials, clinical adverse reactions reported in >5% of patients in any treatment group are shown in Table 2 below.
| |
| | |
| {|
| |
| |[[File:Lovastatin02.jpg|thumb|800px]]
| |
| |}
| |
| | |
| ===Postmarketing Experience===
| |
| The following adverse reactions have been identified during post-approval use of Altoprev® and/or are class effects of HMG CoA reductase inhibitors (statins). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
| |
| | |
| '''Skeletal''': muscle cramps,[[ myalgia]], [[myopathy]], [[rhabdomyolysis]], [[arthralgias]].
| |
| | |
| There have been rare reports of immune-mediated necrotizing myopathy associated with statin use [see Warnings and Precautions (5.1)].
| |
| | |
| '''Neurological''': dysfunction of certain cranial nerves (including alteration of taste, impairment of extra-ocular movement, facial paresis), tremor, [[dizziness]], [[vertigo]], [[paresthesia]], [[peripheral neuropathy]], [[peripheral nerve palsy]], [[psychic disturbances]], [[anxiety]], [[insomnia]], [[depression]].
| |
| | |
| There have been rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. These cognitive issues have been reported for all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).
| |
| | |
| '''Hypersensitivity Reactions''': An apparent [[hypersensitivity]] syndrome has been reported rarely which has included one or more of the following features: [[anaphylaxis]], [[angioedema]], [[lupus erythematous-like syndrome]], [[polymyalgia rheumatica]], [[dermatomyositis]], [[vasculitis]],[[ purpura]], [[thrombocytopenia]],[[ leukopenia]], hemolytic [[anemia]], positive ANA, ESR increase, [[eosinophilia]],[[ arthritis]], [[arthralgia]],[[ urticaria]], [[asthenia]], [[photosensitivity]], fever, chills, flushing,[[ malaise]], [[dyspnea]], [[toxic epidermal necrolysis]], [[erythema multiforme]], including [[Stevens-Johnson syndrome]].
| |
| | |
| '''Gastrointestinal''':[[ pancreatitis]], [[hepatitis]], including [[chronic active hepatitis]], [[cholestatic jaundice]], fatty change in liver; and rarely, cirrhosis, fulminant hepatic necrosis, and [[hepatoma]]; [[anorexia]], [[vomiting]], fatal and non-fatal hepatic failure.
| |
| | |
| '''Skin''': [[alopecia]], [[pruritus]]. A variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails) have been reported.
| |
| | |
| '''Reproductive''': [[gynecomastia]], loss of libido, [[erectile dysfunction]].
| |
| | |
| '''Eye''': progression of [[cataract]]s (lens opacities), [[ophthalmoplegia]].
| |
| | |
| '''Laboratory Abnormalities''': elevated transaminases, alkaline phosphatase, γ-glutamyl transpeptidase, and [[bilirubin]]; [[thyroid function abnormalities]].
| |
| | |
| <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ALTOPREV (LOVASTATIN) TABLET, EXTENDED RELEASE [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e8b6ccc2-e6e7-45fd-ab66-c312bcbe2b01 | publisher = | date = | accessdate = 13 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
|
| |
|
| [[Category:Statins]] | | [[Category:Statins]] |